CN Patent

CN118434422A — 抗体-药物缀合物和rasg12c抑制剂的组合

Assigned to AstraZeneca UK Ltd · Expires 2024-08-02 · 2y expired

What this patent protects

提供了用于组合施用抗HER2抗体‑药物缀合物与RASG12C抑制剂的药物产品。还提供了治疗用途和方法，其中该抗体‑药物缀合物和该RASG12C抑制剂被组合施用于受试者。

USPTO Abstract

提供了用于组合施用抗HER2抗体‑药物缀合物与RASG12C抑制剂的药物产品。还提供了治疗用途和方法，其中该抗体‑药物缀合物和该RASG12C抑制剂被组合施用于受试者。

Drugs covered by this patent

Patent Metadata

Patent number
CN118434422A
Jurisdiction
CN
Classification
—
Expires
2024-08-02
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.